Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 03, 2020 07:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis

The study demonstrated seladelpar to be efficacious, safe and well-tolerated78.2% of patients on seladelpar 10 mg versus 12.5% on placebo achieved the primary composite outcome after only 3 months...
July 23, 2020 08:00 ET | Source: CymaBay Therapeutics, Inc.

FDA Lifts All Clinical Holds on Seladelpar

Clinical hold lifted on seladelpar INDs in NASH, PBC and PSC Re-initiating clinical development focusing first on Phase 3 for PBC NEWARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- CymaBay...
June 19, 2020 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Presents Data at Digestive Disease Week 2020 Online Education

Data from previously completed open-label phase 2 study supports potential for seladelpar to improve pruritus (itching) in patients with PBC Improvements in other quality-of-life parameters also...
June 05, 2020 17:00 ET | Source: CymaBay Therapeutics, Inc.

Notice of Change of Location of Annual Meeting of Stockholders to be Held on June 23, 2020

NEWARK, Calif., June 05, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
May 11, 2020 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports First Quarter 2020 Financial Results and Provides Corporate Update

Independent expert panel unanimously concludes there is no clinical, biochemical or histological evidence of seladelpar-induced liver injury in the Phase 2b NASH study Panel unanimously supports...
May 04, 2020 16:43 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Report First Quarter 2020 Financial Results on Monday, May 11

NEWARK, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
March 12, 2020 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports Fourth Quarter and Fiscal Year End 2019 Financial Results and Provides Corporate Update

Investigating unexpected findings from Phase 2b study of seladelpar in NASH In parallel, board and management evaluating all potential strategic alternatives to maximize shareholder value and...
March 05, 2020 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 12

NEWARK, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
January 29, 2020 16:15 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Publishes Shareholder Letter

NEWARK, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
November 25, 2019 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Halts Clinical Development of Seladelpar

NEWARK, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...